MoneyWorks4Me

Lupin informs about press release

12 Apr 2024 Evaluate

Lupin has informed that it enclosed a Press Release as regards, the successful completion of GMP Inspection by the U.S. FDA, of the Company’s API manufacturing facility located at Dabhasa, India. The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations. 

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2176.95 -13.05 (-0.60%)
25-Aug-2026 11:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1919.00
Dr. Reddys Labs. 1186.60
Cipla 1421.60
Lupin 2176.95
Zydus Lifesciences 1096.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: